Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | ATM | Q13315 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | IGLV6-57 | P01721 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 3/20 | 0.47 |
| ▸ | CASP7 | P55210 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20322872 | 0.83 | NPSR1 (0.48) | KMT2AMEN1IGLV6-57NPSR1CYP1A2 | |
| SCHEMBL27381939 | 0.76 | AHR (0.45) | ALDH1A1KMT2AMAPTMEN1GLA | |
| SCHEMBL1132513 | 0.74 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPTMEN1GLA | |
| SCHEMBL21518484 | 0.74 | SMN1; SMN2 (0.43) | ALDH1A1KMT2AMAPTMEN1MAPK1 | |
| SCHEMBL12106085 | 0.74 | MEN1 (0.52) | ALDH1A1KMT2AMAPTMEN1L3MBTL1 | |
| SCHEMBL23046692 | 0.73 | AHR (0.42) | ALDH1A1KMT2AMAPTMEN1GLA | |
| SCHEMBL20323095 | 0.73 | GABRP (0.47) | ALDH1A1KMT2AMAPTMEN1GLA | |
| SCHEMBL21968642 | 0.73 | AHR (0.52) | ALDH1A1KMT2AMAPTMEN1GLA | |
| SCHEMBL14295300 | 0.73 | AHR (0.52) | ALDH1A1KMT2AMAPTMEN1GLA | |
| SCHEMBL24623784 | 0.73 | AHR (0.52) | ALDH1A1KMT2AMAPTMEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560928-B1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2020-03-31 | — | — | US | disclosed |
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3560928-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2019-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | IDO1, IDO2, INMT | ALDH1A1 735/4885KMT2A 209/4885MAPT 1300/4885 |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | IDO1, IDO2, INMT | ALDH1A1 376/4885KMT2A 367/4885MAPT 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.